Nature's Fynd

Nature's Fynd is one of the best-capitalized fermentation-protein companies in the world, having raised a $350M Series C in 2021 (led by SoftBank Vision Fund 2) that brought total financing over $500M, with a marquee backer list — Breakthrough Energy Ventures, Generation Investment Management, ADM's and Danone's venture arms, and individual backers reported to include Bill Gates and Jeff Bezos. Its differentiator is genuinely novel science: Fy, a complete protein with all nine essential amino acids, grown by fermenting Fusarium strain flavolapis, a microbe discovered in Yellowstone's geothermal springs during NASA-funded research, in a low-land, low-water, low-energy process. Crucially, Fy is a platform ingredient, not a one-product bet — the company has already turned it into dairy-free yogurts, cream cheese, and meatless breakfast patties, and can formulate across both dairy-style and meat-style categories, giving it multiple shots on goal from one fermentation stack. It reached retail including Whole Foods, won Gold in the Sustainable Food category at the 2025 Edison Awards, and continues to build out its technical leadership. The FDA has cleared its protein. In a sector where most companies are single-product and undercapitalized, a well-funded platform with defensible IP (a proprietary organism), FDA clearance, and the ability to address the enormous dairy and breakfast-protein categories simultaneously is positioned to outlast the shakeout and consolidate demand as weaker rivals fold.